💡 Board approved preferential issue to raise ~₹48.6 Cr for strengthening integrated healthcare platform.
What Happened
The Board of Directors of Sat Kartar Life Limited (formerly Sat Kartar Shopping Limited) has approved a preferential issue to raise funds. The company will issue equity shares and convertible warrants to raise approximately ₹48.6 crore from 15 non-promoter investors. The board also approved acquiring an additional 24% stake in its subsidiary, Plantomed Neutraceuticals Private Limited, to make it a wholly owned subsidiary.
Key Details
- Company: Sat Kartar Life Limited
- Event Type: Fundraise
- Filing Date: 18-Apr-2026 18:56:40
- NSE Filing: View Document
Why It Matters
This fundraise is a strategic step for Sat Kartar Life to strengthen its integrated healthcare platform, which combines Ayurveda products and hospital-based care. The capital infusion from institutional and high-net-worth investors signals external confidence in the company's growth plans. Making Plantomed a wholly owned subsidiary will give the company full control over its Ayurveda nutraceuticals business, allowing for better operational alignment and brand consolidation. The funds are intended to drive scalable growth and enhance long-term value for stakeholders.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free